FY2025 EPS Estimates for Surrozen Decreased by HC Wainwright

Surrozen, Inc. (NASDAQ:SRZN) – Investment analysts at HC Wainwright reduced their FY2025 EPS estimates for shares of Surrozen in a note issued to investors on Monday, November 10th. HC Wainwright analyst M. Caufield now expects that the company will post earnings of ($6.46) per share for the year, down from their previous estimate of ($2.83). The consensus estimate for Surrozen’s current full-year earnings is ($8.49) per share.

Surrozen (NASDAQ:SRZN) last announced its earnings results on Friday, November 7th. The company reported ($3.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($2.44). The firm had revenue of $0.98 million for the quarter. Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surrozen in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $38.50.

Surrozen Trading Up 6.8%

Shares of SRZN stock opened at $12.94 on Thursday. The company has a market capitalization of $110.90 million, a price-to-earnings ratio of -0.58 and a beta of 0.64. Surrozen has a 1-year low of $5.90 and a 1-year high of $18.17. The stock’s fifty day simple moving average is $12.79 and its 200-day simple moving average is $10.56.

Institutional Trading of Surrozen

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC lifted its holdings in Surrozen by 22.6% in the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after purchasing an additional 5,702 shares during the last quarter. Heights Capital Management Inc. bought a new position in Surrozen during the first quarter valued at about $524,000. Armistice Capital LLC bought a new stake in shares of Surrozen during the second quarter valued at approximately $536,000. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Surrozen by 37.1% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 88,653 shares of the company’s stock worth $1,034,000 after acquiring an additional 24,000 shares during the period. Finally, Braidwell LP bought a new position in Surrozen during the second quarter worth about $1,252,000. Institutional investors and hedge funds own 66.57% of the company’s stock.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.